Clinical Trials Logo

Psoriasis clinical trials

View clinical trials related to Psoriasis.

Filter by:

NCT ID: NCT05056168 Not yet recruiting - Psoriasis Clinical Trials

Validation of a Dermatology-Specific Treatment Satisfaction Instrument

Start date: September 13, 2021
Phase:
Study type: Observational

The primary objective of this study is to validate a dermatology-specific questionnaire that assesses patient satisfaction with their treatments across various inflammatory dermatology diseases.

NCT ID: NCT05051943 Recruiting - Clinical trials for Rheumatoid Arthritis

A Prospective Observational Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response

OPALE
Start date: September 28, 2020
Phase:
Study type: Observational

The aim of the study is to describe the real-world profile of patients treated with adalimumab FK in gastroenterology, dermatology or rheumatology in order to evaluate in this population the predictive factors of therapeutic response (in particular nutritional status) and generate hypothesis between nutritional status and therapeutic response.

NCT ID: NCT05046899 Not yet recruiting - Plaque Psoriasis Clinical Trials

Investigation With BiopH+Psoriasis Medical Bath in Subject With Mild to Moderate Plaque Psoriasis.

Start date: September 14, 2021
Phase: N/A
Study type: Interventional

The purpose of this investigation is to assess performance and safety of BIOpH+ Psoriasis Medical Bath in comparison to a comparative device.

NCT ID: NCT05044234 Not yet recruiting - Psoriasis Clinical Trials

A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis

Start date: November 10, 2021
Phase: Phase 2
Study type: Interventional

Psoriasis is a chronic disease characterized by marked inflammation and thickening of the skin that results in thick, scaly skin plaques. This study will assess how safe and effective cedirogant (ABBV-157) is compared to placebo in adult participants with moderate to severe psoriasis. Efficacy and safety-related measurements are assessing disease activity in participants with plaque psoriasis. Cedirogant (ABBV-157) is an investigational drug being developed for the treatment of chronic plaque psoriasis. Participants will be put into 1 of 4 groups, called treatment arms and each group receives a different treatment. There is a 1 in 4 chance that participants will be assigned to placebo. Approximately 200 adult participants with moderate to severe plaque psoriasis will be enrolled at approximately 45 sites. Participants will receive oral daily doses of cedirogant or placebo capsules for 16 weeks. There may be a higher burden for participants in this study compared to usual standard of care. Participants will attend regular visits per routine clinical practice. The effect of the treatment will be checked by medical assessments, checking for side effects, and questionnaires.

NCT ID: NCT05042635 Not yet recruiting - Plaque Psoriasis Clinical Trials

Sequential Treatment of Psoriasis With Traditional Chinese and Western Medicine

Start date: October 1, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to objectively and standardly evaluate the clinical efficacy and safety of sequential treatment of psoriasis with traditional Chinese and Western medicine through a multi-center, randomized, double-blind, placebo-controlled trial.

NCT ID: NCT05036889 Not yet recruiting - Plaque Psoriasis Clinical Trials

A 16-week Randomized Evaluation of the Impact of Mind.Px Application on Response to Biologic Treatment in Patients Suffering From Plaque Psoriasis Through Clinical Utility and Health Outcomes.

MATCH
Start date: September 24, 2021
Phase: N/A
Study type: Interventional

This protocol describes randomized, multicenter, blinded (subjects), 16-week, controlled study in parallel balanced groups of psoriasis (Ps) patients to evaluate the impact of Mind.Px on response to biologic treatments. Patients enrolled in this study will be required to have diagnosis of Ps and a total score ≥10 on the PASI and the identified study-lesion must have a PGA severity ≥3 on a 5-point scale of 0 to 4. Patients suffering from Ps will be enrolled in the study and randomized on a 1:1 basis to treatment as usual (TAU) or to treatment decision utilizing Mind.Px (MND). Both groups will have a dermal patch applied and analyzed. The TAU group will not be provided the results of the dermal patch until the end of the last study visit. The MND group will be provided the results of the dermal patch upon the completion of the analysis.

NCT ID: NCT05028582 Recruiting - Scalp Psoriasis Clinical Trials

Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)

ARRECTOR
Start date: August 24, 2021
Phase: Phase 3
Study type: Interventional

This study will assess the safety and efficacy of ARQ-154 foam vs vehicle applied once daily for 8 weeks by subjects with scalp and body psoriasis.

NCT ID: NCT05020249 Not yet recruiting - Clinical trials for Moderate to Severe Plaque Psoriasis

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis

Start date: September 2021
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the efficacy and safety of bimekizumab compared with placebo.

NCT ID: NCT05010044 Not yet recruiting - Psoriasis Clinical Trials

MBCT for Psoriasis Patients With Anxiety and Depression

Start date: August 2021
Phase: N/A
Study type: Interventional

This study investigates the effectiveness of a 24-week mindfulness intervention in reducing symptoms in psoriasis patients with anxiety and depression.

NCT ID: NCT05004727 Not yet recruiting - Psoriasis Clinical Trials

Multi-Center PAMPA Study

PAMPA
Start date: October 1, 2021
Phase: Phase 4
Study type: Interventional

This is a multi-center (North-America), randomized, double-blind, placebo-controlled, wait-list, interventional, preventive trial of guselkumab in high-risk psoriasis patients compared to non-biologic standard of care. The primary objective of our proposed trial will be to test the hypothesis that a prolonged, unresolved skin inflammation coupled with musculoskeletal power-doppler ultrasound (MSKPDUS) abnormalities driven by IL-23 increase the risk for transition into PsA and that an intervention that targets one of these pivotal molecules (i.e., Guselkumab) will: 1. Diminish MSKPDUS findings at 24 weeks, and 2. Significantly reduce or prevent the emergence of synovio-enthesial phenotype at year 2.